caa a22 4500 477072712 CHVBK 20180405111431.0 cr unu---uuuuu 170330e19961001xx s 000 0 eng 10.1007/BF00823589 doi (NATIONALLICENCE)springer-10.1007/BF00823589 Effects of isradipine sustained release on platelet function and fibrinolysis in essential hypertensives with or without other risk factors [Elektronische Daten] [G. Ranieri, V. Filitti, A. Andriani, M. Bonfantino, G. Lamontanara, A. Cavallo, M. Milani, R. De Cesaris] Summary: The aim of this study was to assess the chronic effects of a highly selective dihydropiridine calcium channel blocker, israpidine, in its sustained release form (I-SRO), on platelet functions and fibrinolytic parameters in subjects with essential hypertension (EH) combined or not with other well-known cardiovascular risk factors, such as cigarette smoking (EH+S) and type II diabetes mellitus (EH+DM). Thirty-six patients with essential hypertension with sitting diastolic blood pressures of 96-104 mmHg without (EH, n=12) or with other risk factors (EH+S, n=12, EH+DM, n=12) were enrolled. After a 4-week, single-blind, placebo run-in period, the subjects received I-SRO 5 mg once daily for 18 weeks. After both placebo and 6 and 18 weeks of I-SRO treatment, the following parameters were measured: sitting blood pressure by mercury sphygmomanometer; platelet aggregation, plasma beta-thromboglobulin (BTG), platelet factor-4 (PF4), and plasminogen activator inhibitor 1 (PAI-1) by means of ELISA methods; and euglobulin lysis time before (ELT) and after standardized (10 min) venous occlusion (ELT-VO). In the group of patients as a whole compared with placebo, I-SRO significantly reduced SBP/DBP platelet aggregation, BTG, PF4, ELT, and ELT-VO. Significant reductions in these parameters were also observed in each group. In addition to the antihypertensive effect, I-SRO chronic treatment may favorably affect the platelet function and fibrinolytic system in essential hypertension with or without other cardiovascular risk factors. Kluwer Academic Publishers, 1996 israpidine nationallicence hypertension nationallicence diabetes mellitus nationallicence smoking nationallicence platelet functions nationallicence fibrinolysis nationallicence Ranieri G. Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine, Chair of Medical Therapy, University of Bari Medical School, Bari, Italy aut Filitti V. Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine, Chair of Medical Therapy, University of Bari Medical School, Bari, Italy aut Andriani A. Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine, Chair of Medical Therapy, University of Bari Medical School, Bari, Italy aut Bonfantino M. Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine, Chair of Medical Therapy, University of Bari Medical School, Bari, Italy aut Lamontanara G. Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine, Chair of Medical Therapy, University of Bari Medical School, Bari, Italy aut Cavallo A. Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine, Chair of Medical Therapy, University of Bari Medical School, Bari, Italy aut Milani M. Sandoz Prodotti Farmaceutici Medical Department, Milan, Italy aut De Cesaris R. Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine, Chair of Medical Therapy, University of Bari Medical School, Bari, Italy aut Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10/2(1996-10-01), 119-123 0920-3206 10:2<119 1996 10 10557 https://doi.org/10.1007/BF00823589 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00823589 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Ranieri G. Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine, Chair of Medical Therapy, University of Bari Medical School, Bari, Italy aut NATIONALLICENCE 700 1- Filitti V. Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine, Chair of Medical Therapy, University of Bari Medical School, Bari, Italy aut NATIONALLICENCE 700 1- Andriani A. Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine, Chair of Medical Therapy, University of Bari Medical School, Bari, Italy aut NATIONALLICENCE 700 1- Bonfantino M. Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine, Chair of Medical Therapy, University of Bari Medical School, Bari, Italy aut NATIONALLICENCE 700 1- Lamontanara G. Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine, Chair of Medical Therapy, University of Bari Medical School, Bari, Italy aut NATIONALLICENCE 700 1- Cavallo A. Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine, Chair of Medical Therapy, University of Bari Medical School, Bari, Italy aut NATIONALLICENCE 700 1- Milani M. Sandoz Prodotti Farmaceutici Medical Department, Milan, Italy aut NATIONALLICENCE 700 1- De Cesaris R. Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine, Chair of Medical Therapy, University of Bari Medical School, Bari, Italy aut NATIONALLICENCE 773 0- Cardiovascular Drugs and Therapy Kluwer Academic Publishers 10/2(1996-10-01), 119-123 0920-3206 10:2<119 1996 10 10557 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer